MyelinWatch EL
← Pipeline
Human safety / PK onlyAnnounced / plannedRegulatory development

Phase 1 • healthy volunteers

PTD802

GPR17 antagonist

Practical availability: Research record — not presented as established care

Compound / intervention
GPR17 antagonist
Mechanism
GPR17 antagonism
Development stage
Phase 1 • healthy volunteers
Status
First-in-human programme authorised
Population / locations
First-in-human programme • no MS patient sites yet
Evidence level
Healthy-volunteer development • no MS efficacy data
Next substantive checkpoint

Safety, tolerability and PK before any efficacy study in people with MS

Official programme sourceOpen source ↗Last checked: 16 Sep 2026

Related substantive developments

Human safety / PK onlyAnnounced / plannedRegulatory development

Phase 1

PTD802: FDA clearance for the first human study

The FDA cleared the IND for PTD802, an oral selective GPR17 antagonist designed to release a brake on OPC maturation and promote remyelination.

Practical availability: Research record — not presented as established care

What this means clinically

This is an important step from laboratory work to human testing, but no efficacy data in people with MS are available yet.

Source quality: Official company regulatory announcement • no efficacy data yet

Official programme sourcePheno Therapeutics ↗